Most gene therapy failures don't die in the lab. They die in the clinic, when a patient's healthy cells start expressing a therapeutic gene they were never supposed to touch. The gene itself works fine. The problem is the regulatory wrapper around it: nobody knows exactly how to tell a gene to turn on in a cancer cell and stay silent in everything else. That's the gap Origin is trying to close.
Origin is a four-person YC W2026 startup building Axis, an AI model that designs the regulatory DNA sequences that control gene expression. Not the genes themselves. The switches. The volume dials. The tissue-specific on/off instructions that sit upstream of the protein-coding sequence and determine whether a gene fires in a lung tumor or a liver cell or stays quiet in both. This is harder than it sounds, and the scientific establishment has been stuck on it for decades.
Why Regulatory DNA Is the Bottleneck Nobody Talks About
Cell and gene therapy is one of the few areas in medicine where you can theoretically cure a disease with a single treatment. Replace a broken gene. Reprogram immune cells to hunt tumors. The logic is clean. The execution is not.
The core safety problem: when you deliver a therapeutic gene, you need to ensure it expresses strongly enough in diseased cells to work, and weakly enough (or not at all) in healthy tissue to avoid toxicity. That precision is encoded in the regulatory DNA flanking the gene. Historically, researchers have used naturally occurring regulatory sequences pulled from the genome, hoping they'll behave appropriately in the new context. Sometimes they do. Often they don't, and patients get hurt.
The global cell and gene therapy market sits at roughly $44.75 billion in 2026, and the toxicity problem is a primary reason more therapies aren't making it through trials. Origin's founders, CEO Yash Rathod (UIUC Computer Science, previously computer vision and reinforcement learning research) and CTO Malhar Bhide (UIUC, previously Wadhwani AI and Automorphic, published disease modeling research in Nature Scientific Reports while still in high school) are betting that synthetic, AI-designed regulatory sequences can outperform anything evolution happened to leave behind.



